fentiazac

Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of joint and muscular pain. It acts by inhibiting prostaglandin synthesis through non-selective inhibition of both cyclooxygenase (COX)-1 and COX-2 enzymes. Fentiazac exhibits analgesic, anti-inflammatory, and antipyretic properties. It was first described in 1974 and synthesized using the Hantzsch thiazole synthesis[1][5][7]. The drug has been studied for use in conditions such as arthritis (rheumatoid arthritis, osteoarthritis), tendinitis, bursitis, periodontitis, and other musculoskeletal inflammatory disorders[3][6][8]. Its market status is currently unknown but it is assumed to be discontinued[1].

Brand names

NorvedanDonorestFlogene

Other names

2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid18046-21-4